Your Solutions
BIOMEDTRACKER
Real-time Event Tracking & Drug Development Analysis
管線研發追蹤、獲批前景分析、商業資訊、調研報告
DATAMONITOR HEALTHCARE
Disease Competitive Analysis, 10-20 Years Market Forecast, KOL Insights
疾病競爭分析、10-20年市場預測、KOL專訪
Meet the team
Julie Guan (China)
Head of Strategic Accounts
Citeline
Youmin Zhu (China)
Client Success Manager
Citeline
Training & Help
We provide product training support via online sessions/pre-recorded materials, please click below to access relevant contents, or reach out to this email for any customized training request: [email protected]
我們提供各產品的使用培訓支持，請點擊下列查閲相關培訓資源，若有特定培訓需求或安排則可聯絡：[email protected]
For access or technical issues, please contact your dedicated support team via 'Meet the Team', or contact Client Service team via below email:
若有任何登錄問題，請切換至Meet the Team版面並聯絡對接服務團隊，或可聯絡全球/亞太客服團隊：
Global - [email protected] (English only)
APAC - [email protected] (via English/Chinese)
Require Research Support?
Ask-the-Analyst™
Ask-the-Analyst™
Your status as a loyalty partner includes unlimited access to our highly acclaimed Ask-the-Analyst™ service. With a 24-hour response time, Ask-the-Analyst offers you authoritative information to help you make faster, smarter business decisions.
作爲重點合作夥伴，貴司用戶均可無限量使用「Ask-the-Analyst™」分析師咨詢服務。分析師團隊將會在24小時内回復（工作日），并爲您提供信息收集或專業見解，最終助您做出更快、更明智的業務決策。
Our Ask-the-Analyst team of industry experts leverages the complete suite of pharma intelligence products and publicly available sources to bring you the answers you’re looking for, while your information and all questions received are strictly confidential.
由業界專家組成的Ask the Analyst團隊將結合内部數據與公開領域資源爲您提供相關信息支持，您的個人資訊與提問内容均會被嚴格保密。
Latest Pharma Monthly Newsletter
Edition: January 2026
EDITORIAL CONTENTS (incl. Podcasts, Webinars)
- Notable Podcast: Drug Fix: Pazdur’s CNPV Problems, Could US FDA Release Unapproved Product Action Packages?
- Notable Webinar: 2026 Preview: Navigating Pharma’s Critical Year
- Notable Webinar: Inside #JPM2026: The Stories Behind the Summit
DEALS & FINANCING (incl. M&As, Licensing, Financing)
- Notable M&A: GSK to Buy RAPT Therapeutics for $2.2B
- Notable M&A: Boston Scientific Enters Agreement to Acquire Penumbra in $15B Cash and Stock Transaction
- Notable Licensing: RemeGen Lands $650M Up Front in PD-1/VEGF Deal with AbbVie totalling $5.6B
- Notable Licensing: AstraZeneca Enters Collaboration with CSPC for Next-Generation Obesity and T2D Therapeutics totalling $4.7B ($1.2B upfront)
- Notable Financing: AirNexis Launches with $200M Series A Round
- Notable Financing: Aktis Oncology Nets $339.8M in IPO
KEY R&D EVENTS (incl. Top-line Readouts, Analyst Commentary, Approval/CRL)
- Notable Analysis: Pierre Fabre | Tabelecleucel | EBV+ PTLD (Phase 3): “Second CRL derails Ebvallo in Epstein Barr virus-positive post-transplant lymphoproliferative disease…”
- Notable Analysis: Incyte | Monjuvi | DLBCL (Approved): “Monjuvi heading for potential first line approval in multiple myeloma after Phase 3 frontMIND win…”
- Notable Analysis: Eli Lilly | Taltz | Obesity (Phase 3): “Eli Lilly’s psoriasis drug Taltz in combination with Zepbound shows promise in obese PsA adults…”
- Notable Analysis: Rezolute | RZ-358 | Congenital Hyperinsulinism (Phase 3): “Rezolute’s lone asset, RZ-358, fails Phase III in congenital hyperinsulinism, casting doubts on future development…”
- Notable Analysis: MoonLake | sonelokimab | Hidradenitis Suppurativa (Phase 3): “MoonLake reports positive FDA Type B meeting outcome for sonelokimab in Hidradenitis Suppurativa…”
RESEARCH REPORTS (incl. Forecast, Thought Leadership, KOL Interview)
- Notable Report: 2026 World Preview: Navigating Pharma’s Critical Year
- Notable Report: JPM 2026 Post-Conference Report | Presentation Slides (230+)
- Notable Report: Psychedelic Symposium 2025
- Notable Report: Gene, Cell, & RNA Therapy Landscape Q4 2025
- Notable Report: Pharma Forecasting Trends for 2026: What’s Shaping the Year Ahead
- Notable Report: An Alphabet Soup of 2026 Predictions: GLP-1s, ICH, GCP, CAR-T, AI & More
- Notable Report: Navigating China’s Rise: Strategic Playbook for Global Pharma
- Notable Report: Disease & Market Forecast: Duchenne Muscular Dystrophy (DMD)
- Notable Report: KOL Interview: Cervical Cancer | Endometrial Cancer | Narcolepsy | Dry AWD
Latest Editorial Podcasts
